The diagnostic sector faces a “challenging set-up” in 2022 as economic slowdowns in the U.S. and Europe dampen hopes of a post-pandemic recovery in volumes, according to analysts at Goldman Sachs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,